What it's for (Indications)
- Amantadine is indicated for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions.
- For Parkinson's disease, it is utilized in the management of idiopathic Parkinsonism, postencephalitic Parkinsonism, and symptomatic Parkinsonism following cerebral trauma.
- Its therapeutic benefits in Parkinson's often include the amelioration of cardinal motor symptoms such as bradykinesia, rigidity, and tremor, and it can be used as monotherapy in early stages or as an adjunct to levodopa-containing regimens.
- In the context of drug-induced extrapyramidal reactions, amantadine is effective in reducing symptoms like dystonia, akathisia, and akinesia, often caused by antipsychotic medications, though it is not indicated for tardive dyskinesia.
- Historically, amantadine has also been approved for the prophylaxis and treatment of respiratory tract illness caused by influenza A virus strains.
- However, due to widespread antiviral resistance, its use for influenza A is now largely limited and not generally recommended by public health organizations for current strains.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for amantadine must be carefully individualized based on the specific indication, the patient's age, and critically, their renal function. For Parkinson's disease and drug-induced extrapyramidal reactions, the typical adult starting dosage is 100 mg orally once or twice daily. This can be gradually increased based on clinical response and tolerability, generally not exceeding 400 mg per day in divided doses to minimize central nervous system adverse effects. In elderly patients, a starting dose of 100 mg once daily is often recommended. For influenza A prophylaxis or treatment, the standard adult dose is 100 mg orally twice daily. However, significant dosage adjustments are imperative for patients with impaired renal function. For creatinine clearance values below 50 mL/min, the dose must be reduced and the dosing interval extended. In severe renal impairment (e.g., <15 mL/min), amantadine may be contraindicated or require substantial dose reduction and close monitoring. Monitoring of renal function is essential throughout therapy. |
Safety & Warnings
Common Side Effects
- Amantadine is associated with a spectrum of potential side effects, predominantly affecting the central nervous system (CNS), gastrointestinal (GI) system, and cardiovascular system.
- Common CNS adverse effects include dizziness, lightheadedness, insomnia, nervousness, and difficulty concentrating, which are often transient and may improve with dose adjustment or continued therapy.
- Psychiatric symptoms such as hallucinations, confusion, agitation, and nightmares are notable, particularly in elderly patients or those with pre-existing psychiatric conditions, and warrant careful monitoring.
- Gastrointestinal disturbances include nausea, vomiting, dry mouth, constipation, and anorexia.
- Cardiovascular side effects can manifest as orthostatic hypotension, peripheral edema, and rarely, exacerbation of congestive heart failure.
- A distinctive dermatological side effect is livedo reticularis, a mottled, purplish discoloration of the skin, typically on the lower extremities, which is generally benign and reversible upon drug discontinuation.
- Other less common but serious effects include seizures, suicidal ideation, and acute renal failure.
Serious Warnings
- Black Box Warning: As per current FDA guidelines, amantadine (e.g., PK-Merz) does not carry a formal 'Black Box Warning.' However, clinicians and patients should be acutely aware of several significant safety concerns that warrant careful consideration. These 'Serious Warnings' include the risk of severe withdrawal syndrome upon abrupt discontinuation, particularly in patients with Parkinson's disease, which can lead to a marked worsening of Parkinsonian symptoms, or even neuroleptic malignant syndrome-like symptoms (e.g., fever, muscular rigidity, altered mental status, and autonomic instability). Psychiatric adverse events, such as hallucinations, confusion, agitation, and psychosis, are a notable risk, especially in elderly patients or those with pre-existing psychiatric conditions, necessitating vigilant monitoring and potential dose adjustment or discontinuation. Impulse control disorders (e.g., pathological gambling, increased libido, compulsive shopping) have been reported with dopaminergic therapies, including amantadine, and patients should be monitored for these behavioral changes. Amantadine can also exacerbate congestive heart failure and lead to peripheral edema, requiring careful assessment and monitoring in patients with cardiovascular comorbidities. Furthermore, substantial dosage adjustments are critical in patients with renal impairment to prevent accumulation and toxicity, given the drug's primary renal elimination.
- Several critical warnings and precautions are paramount when prescribing or administering amantadine.
- Patients with a history of congestive heart failure, peripheral edema, or orthostatic hypotension require close monitoring, as amantadine can exacerbate these conditions.
- Its use should be approached with extreme caution in patients with a history of seizures or epilepsy, as it may lower the seizure threshold.
- Psychiatric adverse events, including hallucinations, delusions, confusion, agitation, and depression, are well-documented, particularly in elderly individuals or those with a history of mental disorders; careful patient selection and vigilance are crucial.
- Abrupt discontinuation of amantadine, particularly in patients with Parkinson's disease, can precipitate severe withdrawal reactions, including worsening Parkinsonian symptoms, and rarely, neuroleptic malignant syndrome-like symptoms.
- Therefore, gradual tapering is essential.
- Renal impairment significantly impacts amantadine clearance, necessitating substantial dose adjustments to prevent drug accumulation and toxicity.
- Impulse control disorders, such as pathological gambling, increased libido, and compulsive shopping, have been reported in patients treated with dopaminergic therapies, including amantadine; patients should be monitored for these behavioral changes.
How it Works (Mechanism of Action)
Amantadine exerts a multifaceted mechanism of action that contributes to its therapeutic efficacy in Parkinson's disease and its historical antiviral properties. In Parkinson's disease, its primary anti-Parkinsonian effect is believed to involve non-competitive antagonism of N-methyl-D-aspartate (NMDA) receptors. By blocking these ionotropic glutamate receptors, amantadine helps to modulate excessive glutamatergic activity, which is thought to play a role in the pathophysiology of motor dysfunction. Additionally, amantadine potentiates the release of dopamine from presynaptic nerve terminals and inhibits its reuptake, thereby increasing dopamine concentrations in the synaptic cleft. It also exhibits weak anticholinergic properties, which further contribute to its therapeutic effects by balancing the cholinergic and dopaminergic systems in the basal ganglia. For its antiviral action against influenza A virus, amantadine specifically targets the M2 ion channel protein of the virus, disrupting the uncoating process of the virus within the host cell and thereby inhibiting viral replication. This mechanism is strain-specific and resistance can develop.
Commercial Brands (Alternatives)
No other brands found for this formula.